Lactulose Solution
Product Images NDC 61037-471

Product Visual Gallery

This gallery contains 29 technical images submitted to the FDA as part of the official labeling for Lactulose Solution (NDC 61037-471). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bajaj Medical, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

118ml1 (118ml 1)

This is a description of Lactulose Solution, USP - a medication used for the prevention and treatment of portal-systemic encephalopathy. It contains 10g/15ml of lactulose and is meant for oral or rectal administration. The solution has a pH range between 2.5 and 6.5 and contains colors including D&C Yellow No. 10, FD & G Yellow No. 6, and purified water. The solution should be stored in a tight, light-resistant container at controlled room temperature, between 20-25°C (68-77°F) and should not be frozen. The medication is manufactured by B Medica in a 4 oz. (118 ml) container. Patients may find that the solution is more acceptable when mixed with fruit juice, water or milk.*

FDA Label Image

118ml2 (118ml 2)

This is a prescribing information document for lactulose solution USP used for oral or rectal administration in the treatment and prevention of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Lactulose works by causing a decrease in blood ammonia concentration and reducing the degree of portal-systemic encephalopathy. It is poorly absorbed, and urinary excretion is minimal. Clinical studies show that lactulose solution therapy reduces blood ammonia levels by 25-50%, resulting in an improvement in the patient's mental state and EEG patterns.*

FDA Label Image

118ml3 (118ml 3)

The text describes the use of lactulose solution in the treatment of chronic portal-systemic encephalopathy. It also lists contraindications, warnings, precautions, and possible drug interactions for lactulose solution. These include caution in diabetic patients, monitoring for patients undergoing medical procedures, and the risk of loose stools caused by other laxatives during lactulose therapy. The text also notes the lack of available information on the safety of lactulose during pregnancy and nursing.*

FDA Label Image

118ml4 (118ml 4)

This text discusses caution needed in administering medication to nursing women. It also provides information on the use of Lactulose, a drug used to treat constipation and liver disease, in adult and pediatric patients. The text provides instructions for dosage and administration for both oral and rectal administration. Adverse reactions to Lactulose are also discussed.*

FDA Label Image

118ml5 (118ml 5)

This is an output of a prescription medication called Lactulose Solution. The solution is a clear, yellow to golden-yellow liquid supplied in various volume sizes of amber and white plastic bottles with resistant closures and single doses. It contains 667 mg lactulose/mL (10 g/15 mL). The medication is used for preventing and treating portal-systemic encephalopathy, and the recommended dosage is not given in the text. The solution should be stored at 20-25°C (68-77°F) in a tightly closed container and should not be frozen. Prolonged exposure to high temperatures or freezing temperatures may change the medication's color or viscosity, which will affect its therapeutic action. Dispense in a tight, light-resistant container with a chill-resistant closure, and consult a pharmacist before use. The manufacturer's name is Baja Medical, with the address at 415 W Pershing R, Chicago, L 6060 USA, and the package size is 4 oz. (118 ml).*

FDA Label Image

15ml1 (15ml 1)

This is a lactulose solution, USP with 10 g/15mL concentration for oral or rectal administration. It is used for the prevention and treatment of portal-systemic encephalopathy. Each 15 mL single-unit dose includes 10 g lactulose, less than 1.6 g galactose, less than 1.2 g lactose, and 0.1 g or less of fructose. It contains colors and purified water. The solution may be mixed with fruit juice, water, or milk. It should be stored in a light-resistant container at 20-25°C (68-77°F) and should not be frozen. It is manufactured by Bajaj Medical in Chicago and is available in a pack of 100 unit doses. Rx Only.*

FDA Label Image

15ml2 (15ml 2)

This is a prescribing information for Lactulose Solution USP used for the prevention and treatment of portal-systemic encephalopathy. It contains lactulose, a synthetic disaccharide in solution form for oral or rectal administration. Lactulose lowers blood ammonia concentration and reduces the degree of hepatic pre-coma and coma in patients. The solution is contraindicated in patients who require a low galactose diet. Lactulose solution contains galactose and lactose, so it should be used with caution in diabetes. There have been conflicting reports about the concomitant use of neomycin and lactulose solution; other laxatives should not be used. The drug should be used during pregnancy only if clearly needed.*

FDA Label Image

15ml3 (15ml 3)

This is a drug information leaflet for Lactulose Solution, USP, 10 g/15 mL which is indicated for the prevention and treatment of portal-systemic encephalopathy. The leaflet provides information on how to administer the drug orally or rectally, dosages for adults and pediatric, adverse effects, overdosage, and storage conditions. The text recommends that lactulose should be used cautiously in pediatric patients as there is very little information on its use in this group. It also warns against exceeding the recommended dosage which can lead to complications such as diarrhea, nausea, and vomiting. The text further describes the presentation, dosage, and storage conditions of Lactulose solution.*

FDA Label Image

1893ml1 (1893ml 1)

This is a description of Lactulose Solution, USP used for the prevention and treatment of portal-systemic encephalopathy. The solution is to be used orally or rectally, and possibly mixed with fruit juice, water or milk. One tablespoonful (15 mL) contains 10 g lactulose, and ingredients including colors and purified water. It is dispensed and stored in a tight, light-resistant container with a child-resistant closure, and should be stored at 20-25°C. Extreme darkening or turbidity should be avoided. Detail usage indications and dosage should be found in the prescribing Information. The product is manufactured by Bajaj Medical, Chicago, IL 60609 USA.*

FDA Label Image

1893ml2 (1893ml 2)

Lactulose Solution USP is a synthetic disaccharide administered orally or rectally to prevent and treat portal-systemic encephalopathy. It is primarily used for the reduction of blood ammonia levels by decreasing the concentration of ammonia in blood. The medication is considered safe during pregnancy and compatible with breastfeeding. However, caution should be exercised when administering lactulose to diabetic patients and people receiving non-absorbable antacids. Additionally, lactulose treatment should not be mixed with other laxatives, as it could falsely indicate an adequate dose of lactulose has already been achieved. In rare cases in which a patient requires electrocautery procedures during proctoscopy or colonoscopy, a thorough bowel cleansing with non-fermentable solutions is recommended to prevent explosive reactions due to the accumulation of hydrogen gas.*

FDA Label Image

1893ml3 (1893ml 3)

This text provides information on the use, adverse reactions, dosage, administration, and availability of lactulose solution, a medication used for the prevention and treatment of portal-systemic encephalopathy in adults and children. The recommended oral dose for adults is 2 to 3 tablespoons, while infants receive 15 to 10 mL in divided doses. The medication can cause adverse reactions such as abdominal discomfort and diarrhea, and overdose can lead to loss of fluids, hypokalemia, and hypematremia. The medication is available in several sizes, and it should be stored at controlled room temperature. The text also includes manufacturing and product details.*

FDA Label Image

236ml1 (236ml 1)

This is a description of a medicine called Lactulose Solution, USP, indicated for the prevention and treatment of portal-systemic encephalopathy. It can be administered through oral or rectal means and contains 10 g of actose per 15 mL. The solution also has D&C Yellow No. 1 and D & 0¥ello NoJB colors and purified water. The pharmacist should dispense it in a container defined in the USP, with child-resistant features. It should be stored at controlled room temperature and not be frozen.*

FDA Label Image

236ml2 (236ml 2)

Lactulose Solution USP is a synthetic disaccharide administered orally or rectally for the prevention and treatment of portal-systemic encephalopathy. It contains 10 g of lactose in each 15 mL and is also mixed with FD&C Yellow No. 6 and Purified Water. When given orally, Lactulose Solution USP therapy reduces blood ammonia levels and is generally followed by an improvement in the patients' mental state.*

FDA Label Image

236ml3 (236ml 3)

Lactulose solution is a medication used in the treatment of chronic portal-systemic encephalopathy. It may cause protein tolerance and is contraindicated in patients on low galactose diets. It contains galactose and lactose and should be used with caution in patients with diabetes. Patients on lactulose therapy undergoing electrosurgery procedures such as proctoscopy or colonoscopy should be thoroughly cleansed with non-fermentable solutions to prevent explosive reactions. Lactulose therapy may cause hyponatremia and dehydration in infants. Lactulose should not be used with neomycin or non-absorbable antacids. Other laxatives should also not be used during the initial phase of therapy. Animal studies suggest that lactulose does not cause any harm to the fetus; however, its use in pregnant women should be avoided unless necessary. It is not known if lactulose is excreted in human milk.*

FDA Label Image

236ml4 (236ml 4)

This text contains information about the usage, dosage, administration, and side effects of lactulose, a drug prescribed to treat portal-systemic encephalopathy. The text warns against using lactulose if you are breastfeeding without consulting a doctor. It also provides dosage and administration instructions for both oral and rectal administration and highlights possible side effects of using lactulose, including diarrhea, nausea, vomiting, and abdominal discomforts. The text also emphasizes the importance of taking lactulose as prescribed to prevent overdosage.*

FDA Label Image

236ml5 (236ml 5)

Lactulose Solution is a yellow to golden-yellow solution that is supplied in different sizes of amber plastic bottles with child-resistant closures. Under suitable storage conditions, the solution may darken in color, but it will not affect the therapeutic action. The solution contains 867 mg lactulose/mL (10/15 mL) and is typically used for treating and preventing hepatic encephalopathy. The product should be dispensed in a tight, light-resistant container with a child-resistant closure. The recommended storage temperatures are 20-25°C (68-77°F) without freezing. The solution's manufacturer is Bala Medical, located at 415 W Pershing Rd, Chicago, IL 60609 USA. The available size is an 8 oz. (236 ml) bottle, which contains NDC 61037-471-02.*

FDA Label Image

30ml1 (30ml 1)

This is a medication label for a Lactulose Solution, USP used for prevention and treatment of portal-systemic encephalopathy. The solution is administered orally or rectally and is available in 100 cups, with each cup delivering 30mL. Each tablespoonful (15mL) of the solution contains 10g of lactulose and other ingredients such as colors and purified water, with the pH range being between 2.5 and 6.5. The manufacturer is Bajaj Medical and the solution must be stored at 20- 25°C (68-77°F) and should not be frozen. Pharmacists are advised to dispense in a tight, light-resistant container with a child-resistant closure.*

FDA Label Image

30ml2 (30ml 2)

FDA Label Image

30ml3 (30ml 3)

Lactulose is a solution for oral or rectal administration used in the prevention and treatment of portal-systemic encephalopathy. It may cause adverse reactions such as gaseous distention, abdominal discomfort, diarrhea, nausea, and vomiting. The precise frequency of these symptoms is not available. Recommended dosages vary depending on the patient's age and condition, and they should be adjusted to produce 2-3 soft stools daily. Lactulose may be administered via retention enema if necessary. The drug is supplied in amber plastic and white plastic bottles with child-resistant closures, along with unit-dose cups. It should be stored at 20-25°C, protected from freezing and direct light. Lactulose's active ingredient is 667 mg lactulose/mL (10 g/15 mL).*

FDA Label Image

3785ml1 (3785ml 1)

Lactulose Solution USP is a medication indicated for the prevention and treatment of portal-systemic encephalopathy, available for oral or rectal administration. It contains 10 g of lactulose in each 15 mL (one tablespoon), and other components include colors, purified water, and a pH range of 2.5 to 6.5. Although the product may darken slightly, this should not affect its therapeutic action, and extreme darkening or turbidity can signal the need to discontinue use. This medication should be dispensed by a pharmacist in a tight, light-resistant container, and stored at 20-25°C in tightly closed conditions, with child-resistant closure.*

FDA Label Image

3785ml2 (3785ml 2)

Lactulose Solution USP is a medication used for the treatment and prevention of portal-systemic encephalopathy, including hepatic pre-coma and coma stages. It is available in a solution form that can be taken orally or rectally. The solution contains synthetic disaccharide lactulose acid, which decreases blood ammonia concentration and reduces the symptoms of encephalopathy. Lactulose is metabolized by bacteria to form acids that acidify the colon contents, helping to trap and expel trapped ammonium ions. The lactulose solution has been shown to be about as effective as neomycin therapy. Lactulose should be used with caution in patients with underlying liver disease and electrolyte disturbances. Women who are pregnant or nursing should exercise caution when taking lactulose, as there is no enough information available.*

FDA Label Image

3785ml3 (3785ml 3)

Lactulose Solution, USP is a medication used for the prevention and treatment of portal-systemic encephalopathy. The medication is available in different sizes and strengths, and it can be administered orally or rectally. Patients may experience adverse reactions such as gaseous distention, abdominal discomfort, diarrhea, nausea, and vomiting. The dosage should be adjusted as needed. Lactulose Solution, USP should be stored at room temperature and should not be frozen. Pharmacists should dispense the medication in a tight, light-resistant container with a child-resistant closure.*

FDA Label Image

473ml1 (473ml 1)

This text describes a lactulose solution medication with a concentration of 10g/15mL for oral or rectal administration. It is used for the prevention and treatment of portal-systemic encephalopathy. The medication comes in a 16 fl oz (473 mL) bottle and must be stored at 20-25°C (68-77°F). The solution may be more appetizing when mixed with fruit juice, milk or water. It contains several sugars, including lactulose, galactose, lactose, and fructose, as well as colors (D&C Yellow No. 10 and FD&C Yellow No. 6), and purified water. The pH range is between 2.5 and 6.5. The medication must be dispensed by a pharmacist in a tight, light-resistant container with a child-resistant closure.*

FDA Label Image

473ml2 (473ml 2)

Lactulose Solution USP is a synthetic disaccharide for oral or rectal administration used for the prevention and treatment of portal-systemic encephalopathy. The medication contains 10g of lactulose per 15mL of solution, along with less than 1.6g of galactose and less than 1.2g of lactose. Lactulose is used in the colon for the treatment and prevention of portal-systemic encephalopathy to acidify the colonic contents and decrease blood ammonia concentrations. Lactulose has not been found to be well absorbed and is poorly metabolized. It is contraindicated in patients who require a low galactose diet. Lactulose may interact with other medications and should be given with caution. The drug has not been studied extensively for use during pregnancy and lactation, and caution should be exercised in these cases.*

FDA Label Image

473ml3 (473ml 3)

Lactulose is a solution used for the prevention and treatment of portal-systemic encephalopathy. It can be administered orally or rectally, and dosage varies depending on the age of the patient. Adverse reactions include cramping, nausea, vomiting, and excessive dosages leading to complications. The drug must be stored at controlled room temperature and kept tightly closed. The manufacturer recommends dispensing it in a tight, light-resistant container with child-resistant closure. Darkening of the solution may occur, but it does not affect the therapeutic action.*

FDA Label Image

946ml1 (946ml 1)

This is a description of a Lactulose Solution medication. It contains 10 g of lactulose per 15 mL and is intended for oral or rectal administration. The medication is used for the prevention and treatment of portal-systemic encephalopathy. The solution may darken slightly, but its therapeutic action is not affected. It should not be used if extreme darkening or turbidity occurs. It is advisable to mix the solution with fruit juice, water, or milk, as some patients find it more acceptable that way. The medication is dispensed in a light-resistant container with a child-resistant closure. It should be tightly closed and stored at room temperature. The manufacturing of the product is done by Bajaj Medical.*

FDA Label Image

946ml2 (946ml 2)

Lactulose Solution USP is a synthetic disaccharide used for oral or rectal administration for the prevention and treatment of portal-systemic encephalopathy. It is a colonic acidifier that decreases blood ammonia concentration and reduces the degree of portal-systemic encephalopathy. Lactulose is poorly absorbed, and its laxative action expels the trapped ammonium. It is contraindicated in patients who require low galactose intake. Patients undergoing electrocautery procedures during proctoscopy or colonoscopy should have a thorough bowel cleaning with a non-fermentable solution. Lactulose should be used with caution in diabetes and recognized that it is a serious underlying liver disease with complications such as electrolyte disturbance for which other specific therapy may be required. It may cause hyponatremia and dehydration in infants receiving lactulose. There have been conflicting reports about the concomitant use of neomycin and lactulose solution. Caution is needed when lactulose is administered to a nursing woman because many drugs are excreted in human milk.*

FDA Label Image

946ml3 (946ml 3)

Lactulose Solution is a medication used for the prevention and treatment of portal-systemic encephalopathy. It may cause some adverse reactions like abdominal discomfort, nausea, vomiting or diarrhea. In case of overdosage symptoms may include diarrhea, hypokalemia, and hypernatremia. Dosage varies according to age and symptoms, but it is usually prescribed for adults with a dosage of 2 to 3 tablespoonfuls of the solution taken orally for 3 or 4 times per day. The medication may be continued for long-term to lessen severity and prevent recurrence. Lactulose Solution is supplied in different sizes like 1-pint (473ml), 4-ounce (118ml), 8-ounce (236ml), 32-ounce (946ml), 64-ounce (1893ml), 15ml, and 35ml in unit-dose cups. The solution must not be frozen and should be stored at 20-25°C (68-77°F). The medication should be dispensed in a tight, light-resistant container with a child-resistant closure.*

FDA Label Image

Struct (Struct)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.